Get the Stockscreener App
32.01
0.22%
-0.07
Pre-market:
31.84
-0.17
-0.53%
Atricure Inc stock is traded at $32.01, with a volume of 450.26K.
It is down -0.22% in the last 24 hours and down -5.24% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
See More
Previous Close:
$32.08
Open:
$32.73
24h Volume:
450.26K
Relative Volume:
0.82
Market Cap:
$1.61B
Revenue:
$447.57M
Net Income/Loss:
$-38.92M
P/E Ratio:
-38.57
EPS:
-0.83
Net Cash Flow:
$-1.15M
1W Performance:
+1.17%
1M Performance:
-5.24%
6M Performance:
+12.04%
1Y Performance:
+36.50%
1-Day Range:
$31.17
$33.50
1-Week Range:
$31.14
$33.55
52-Week Range:
$18.94
$43.11
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
32.01 | 1.61B | 447.57M | -38.92M | -1.15M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-29-23 | Initiated | UBS | Buy |
| Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Reiterated | Needham | Buy |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-24-20 | Reiterated | Needham | Buy |
| Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Apr-12-19 | Initiated | JP Morgan | Overweight |
| Oct-04-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Stifel | Buy |
| Jun-18-18 | Reiterated | Needham | Buy |
| Apr-27-18 | Reiterated | Needham | Buy |
| Jan-16-18 | Reiterated | Needham | Buy |
| Nov-02-17 | Reiterated | Needham | Buy |
| Jul-28-17 | Reiterated | Needham | Buy |
| May-30-17 | Resumed | Piper Jaffray | Overweight |
| Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
| Oct-28-15 | Reiterated | Needham | Buy |
| Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
Cryoablation Market Set to Witness Significant Growth by 2032 | - openPR.com
AtriCure Announces First Use of the AtriClip PRO-Mini® Device | - GuruFocus
AtriCure launches smaller device for heart surgery By Investing.com - Investing.com South Africa
AtriCure announces first use of newest AtriClip device - MassDevice
AtriCure Reports 1st Use of Newest AtriClip LAA Exclusion System - Medical Product Outsourcing
AtriCure launches smaller device for heart surgery - Investing.com Australia
AtriCure Announces First Use of the AtriClip PRO-Mini® Device - Yahoo Finance
Groundbreaking Miniature Cardiac Device Transforms LAA Management: AtriClip PRO-Mini Debuts - Stock Titan
Dayton’s stocks continue loss streak following election and now tariffs - The Business Journals
AtriCure Drops 25%: Bargain Or Caution Sign? (NASDAQ:ATRC) - Seeking Alpha
AtriCure to Announce First Quarter 2025 Financial Results - MarketScreener
Is AtriCure (NASDAQ:ATRC) A Risky Investment? - simplywall.st
JMP maintains AtriCure stock with $60 target post-Investor Day By Investing.com - Investing.com Canada
When the Price of (ATRC) Talks, People Listen - news.stocktradersdaily.com
Canaccord Genuity Adjusts Price Target on AtriCure to $52 From $66, Maintains Buy Rating - MarketScreener
Oppenheimer maintains AtriCure stock Outperform rating, $45 target By Investing.com - Investing.com Australia
UBS maintains Buy on AtriCure stock, reiterates $60 target By Investing.com - Investing.com Australia
UBS maintains Buy on AtriCure stock, reiterates $60 target - Investing.com
Piper Sandler maintains $50 target on AtriCure stock, cites growth By Investing.com - Investing.com Canada
Piper Sandler maintains $50 target on AtriCure stock, cites growth - Investing.com
Needham maintains Buy on AtriCure stock, $51 target By Investing.com - Investing.com Australia
Needham maintains Buy on AtriCure stock, $51 target - Investing.com
Oppenheimer maintains AtriCure stock Outperform rating, $45 target - Investing.com
BTIG raises AtriCure stock price target to $58, maintains buy By Investing.com - Investing.com South Africa
BTIG raises AtriCure stock price target to $58, maintains buy - Investing.com
AtriCure Highlights Growth and Innovation at Investor Day - TipRanks
Electrophysiology Devices Market Poised for Strong Growth, Projected to Expand at a 9.73% CAGR by 2030, Reports DelveInsight - Barchart.com
Needham maintains AtriCure stock Buy rating, $51 target By Investing.com - Investing.com Canada
11 Analysts Have This To Say About AtriCure - Benzinga
Needham maintains AtriCure stock Buy rating, $51 target - Investing.com India
(ATRC) Investment Analysis - news.stocktradersdaily.com
AtriCure to Host Analyst & Investor Day on March 26, 2025 - Yahoo Finance
AtriCure Investor Day: New Product Pipeline and Financial Targets Coming March 2025 - Stock Titan
AtriCure, Inc. to Host Earnings Call - ACCESS Newswire
AtriCure Independent Director Karen Prange Sells 25% Of Holding - Simply Wall St
(ATRC) Long Term Investment Analysis - Stock Traders Daily
AtriCure (NASDAQ:ATRC) Stock Price Down 6% Following Insider Selling - Defense World
Atricure director Karen Prange sells $232,531 in stock By Investing.com - Investing.com Canada
Atricure Director Makes a Significant Stock Sale! - TipRanks
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
3.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):